Modeling, Clinical and Virology Data From Phase 2 and 3 Studies Support 12-Week Telaprevir Duration in Combination With 24- or 48-Week Peginterferon/Ribavirin

assess the association of HBsAg loss with different clinical phases of HBV and coinfection with HCV or HDV. Method: A total of 3335 patients (2064 male, 1271 female; mean age: 39.5±12.8), who have been HBsAg positive for at least 1 year and those who followed up for at least 6 months are included in the study. HbsAg loss rates in different clinical phases and coinfection with HBV or HDV were assesed. Differences were determined by log-rank test. Results: Among this cohort; 1160 (34.7%) were inactive carriers, 1675 (50.2%) were chronic hepatitis B, 298 (8.8%) were HBV cirrhosis, 77 (2.3%) were chronic HDV hepatitis, 43 (1.2%) were compensated HDV cirhosis, 44 (1.31%) were co-infected with hepatitis B and C. HBsAg loss rates among different groups were depicted in Figure 1. During a mean follow-up period of median 198 week (range: 24–1306 week), annual Hbs Ag loss rates were 1.88% in HBV and HCV co-infection, 1.64% in inactive carriers, 1.14% in HBV cirrhosis, 0.52% in chronic hepatitis B, 0.64% in HDV. No difference of HBsAg loss was observed between compensated and decompensated cirrhosis. None of HDV cirrhotics had seroclearance. 58.5% of HBV and HCV coinfected, 59% of HDV infected, 20% of chronic hepatitis B patients who had loss of HBsAg were treated with interferon or pegylated interferon. Conclusion: Although HDV infection supresses HBV replication, it does not increase the HBsAg loss rates. However, co-infection with HCV increases the seroclerance rates. HBsAg loss was markedly higher among inactive carriers comparing to chronic hepatitis.